GlassScriptPhysician profile
Scott Dm Miller
NPI 1356384754
$686.52
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2021: $11.92 · 2023: $18.46 · 2024: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.55 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $94.48 | 2023-2024 | Akeega, Erleada, Balversa |
| Novartis Pharmaceuticals Corporation | $65.72 | 2019-2024 | |
| Pfizer INC. | $54.95 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $49.22 | 2024 | Tagrisso, Imfinzi |
| Astellas Pharma US INC | $43.15 | 2024 | Veozah, Xtandi |
| Genentech USA, INC. | $40.20 | 2019 | |
| Abbvie INC. | $39.30 | 2024 | |
| Merck Sharp & Dohme LLC | $36.84 | 2024 | Keytruda |
| Lilly USA, LLC | $35.54 | 2019 | |
| Stemline Therapeutics INC. | $35.06 | 2024 | Orserdu |
| Gilead Sciences, INC. | $28.29 | 2021-2024 | |
| Celgene Corporation | $24.95 | 2024 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $20.70 | 2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Mirati Therapeutics, INC. | $18.28 | 2024 | Krazati |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $17.16 | 2019 | |
| Taiho Oncology, INC. | $16.87 | 2024 | |
| Daiichi Sankyo INC. | $15.88 | 2024 | Injectafer |
| Rigel Pharmaceuticals, INC. | $15.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.